294 / 1138
Radiaton oncologists & risk of ‘bystander effect’
We have a continuous need to reflect on:
•
Clinical need for improved treatments?
•
Evidence for efficacy (clinical trials, CER)?
•
Treatment toxicities, especially use of patient
reported outcomes (PRO’s)
•
Cost-effectiveness (incentives and hurdles)